CN100358520C - Edalavon powder for ampoul injection having good stability and its preparation method - Google Patents
Edalavon powder for ampoul injection having good stability and its preparation method Download PDFInfo
- Publication number
- CN100358520C CN100358520C CNB031567797A CN03156779A CN100358520C CN 100358520 C CN100358520 C CN 100358520C CN B031567797 A CNB031567797 A CN B031567797A CN 03156779 A CN03156779 A CN 03156779A CN 100358520 C CN100358520 C CN 100358520C
- Authority
- CN
- China
- Prior art keywords
- edaravone
- water
- injection
- injectable powder
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007924 injection Substances 0.000 title claims abstract description 42
- 238000002347 injection Methods 0.000 title claims abstract description 42
- 239000000843 powder Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 18
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims description 68
- 229950009041 edaravone Drugs 0.000 claims description 67
- 239000000945 filler Substances 0.000 claims description 25
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical group [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 235000010265 sodium sulphite Nutrition 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical group OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- PBDAWQLIMPWEEF-JEDNCBNOSA-M sodium;(2s)-2,6-diaminohexanoate Chemical compound [Na+].NCCCC[C@H](N)C([O-])=O PBDAWQLIMPWEEF-JEDNCBNOSA-M 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 238000009924 canning Methods 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000005262 decarbonization Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000011265 semifinished product Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000010792 warming Methods 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 11
- 239000000654 additive Substances 0.000 abstract 5
- 230000000996 additive effect Effects 0.000 abstract 5
- 230000029219 regulation of pH Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 28
- 238000005352 clarification Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 150000003863 ammonium salts Chemical class 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- FXXMNCZOYVUJEE-UHFFFAOYSA-N C1(=CC=CC=C1)N1N=CCC1=O.CC1(CC(C(=O)O)=CC=C1)C(=O)O Chemical compound C1(=CC=CC=C1)N1N=CCC1=O.CC1(CC(C(=O)O)=CC=C1)C(=O)O FXXMNCZOYVUJEE-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Lot number | Time (moon) | Appearance luster | Clarity of solution and color | PH value | Related substance (%) | Content (%) |
020601 | 0 1 2 3 6 | White lyophilizing block white lyophilizing block white lyophilizing block white lyophilizing block white lyophilizing block | Clarification achromaticity and clarification achromaticity and clarification achromaticity and clarification achromaticity and clarification is colourless | 8.61 8.59 8.62 8.61 8.60 | 0.01 0.02 0.04 0.03 0.03 | 101.0 98.9 100.7 101.9 97.3 |
020602 | 0 1 2 3 6 | White lyophilizing block white lyophilizing block white lyophilizing block white lyophilizing block white lyophilizing block | Clarification achromaticity and clarification achromaticity and clarification achromaticity and clarification achromaticity and clarification is colourless | 8.58 8.60 8.57 8.61 8.60 | 0.02 0.03 0.02 0.02 0.03 | 100.5 99.8 98.4 101.1 100.6 |
020603 | 0 1 2 3 6 | White lyophilizing block white lyophilizing block white lyophilizing block white lyophilizing block white lyophilizing block | Clarification achromaticity and clarification achromaticity and clarification achromaticity and clarification achromaticity and clarification is colourless | 8.60 8.57 8.61 8.60 8.61 | 0.03 0.02 0.03 0.03 0.03 | 99.4 98.0 101.6 99.8 99.3 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031567797A CN100358520C (en) | 2003-09-11 | 2003-09-11 | Edalavon powder for ampoul injection having good stability and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031567797A CN100358520C (en) | 2003-09-11 | 2003-09-11 | Edalavon powder for ampoul injection having good stability and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1493283A CN1493283A (en) | 2004-05-05 |
CN100358520C true CN100358520C (en) | 2008-01-02 |
Family
ID=34240842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031567797A Expired - Fee Related CN100358520C (en) | 2003-09-11 | 2003-09-11 | Edalavon powder for ampoul injection having good stability and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100358520C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019008144A1 (en) * | 2017-07-06 | 2019-01-10 | Treeway Tw001 B.V. | Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders |
US10966960B2 (en) | 2017-01-17 | 2021-04-06 | Treeway Tw001 B.V. | Medical treatment comprising enteral administration of edaravone |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012509339A (en) * | 2008-11-20 | 2012-04-19 | テイコク ファーマ ユーエスエー インコーポレーテッド | Pyrazolone derivative preparation |
CN101601656B (en) * | 2009-07-03 | 2010-08-18 | 王明 | Edaravone liposome injection and new application thereof |
CN102190622B (en) * | 2010-03-15 | 2015-01-07 | 李勤耕 | Water-soluble derivatives of edaravone, preparation method and application thereof |
CN102144964B (en) * | 2010-07-02 | 2013-03-27 | 南京长澳医药科技有限公司 | Stable and safe edaravone injecta |
CN102119920A (en) * | 2010-07-13 | 2011-07-13 | 福建天泉药业股份有限公司 | Edaravone injection and preparation method thereof |
CN102204908B (en) * | 2011-04-07 | 2013-05-15 | 罗诚 | Pharmaceutical composition containing edaravone compound, and preparation method thereof |
CN104163801B (en) * | 2014-01-27 | 2016-08-24 | 洪军 | A kind of edaravone compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440749A (en) * | 2003-03-24 | 2003-09-10 | 南昌弘益科技有限公司 | Edaravone injection for treating acute cerebral thrombus and its prepn |
CN1449754A (en) * | 2003-04-16 | 2003-10-22 | 浙江震元制药有限公司 | Edaravone medicine composition and preparation thereof |
-
2003
- 2003-09-11 CN CNB031567797A patent/CN100358520C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440749A (en) * | 2003-03-24 | 2003-09-10 | 南昌弘益科技有限公司 | Edaravone injection for treating acute cerebral thrombus and its prepn |
CN1449754A (en) * | 2003-04-16 | 2003-10-22 | 浙江震元制药有限公司 | Edaravone medicine composition and preparation thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10966960B2 (en) | 2017-01-17 | 2021-04-06 | Treeway Tw001 B.V. | Medical treatment comprising enteral administration of edaravone |
WO2019008144A1 (en) * | 2017-07-06 | 2019-01-10 | Treeway Tw001 B.V. | Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders |
US20200138712A1 (en) * | 2017-07-06 | 2020-05-07 | Treeway Tw001 B.V. | Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders |
Also Published As
Publication number | Publication date |
---|---|
CN1493283A (en) | 2004-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102068453B (en) | Stable complex vitamin composition and preparation method thereof | |
US8062647B2 (en) | High concentration baclofen preparations | |
CN100358520C (en) | Edalavon powder for ampoul injection having good stability and its preparation method | |
CN102512378B (en) | Stable and safe oxiracetam pharmaceutical composition for injection | |
WO2008086698A1 (en) | A forsythoside injection and preparation thereof | |
WO2018164513A1 (en) | Stable preparation containing bortezomib and preparation method therefor | |
CN110464846B (en) | Meloxicam composition, preparation method and application thereof | |
CN112402371B (en) | Rudesiwei injection and preparation method thereof | |
CN102784382B (en) | Argatroban drug composition and preparation method and application of argatroban drug composition | |
CN103110640B (en) | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection | |
SK2092002A3 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
CN101940557A (en) | Method for preparing fat-soluble vitamin freeze-dried powder injection | |
CN103349644B (en) | Lansoprazole complex micelle medicine composition for injection and preparation method thereof | |
CN1935153A (en) | Lyophilized powder injection containing three B-vitamins and its preparing method | |
CN103083322B (en) | Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection | |
CN103494779B (en) | Andrographolide powder preparation for injection and preparation method thereof | |
CN1663615A (en) | Fructose injection of antibiotic medicine | |
CN109568277A (en) | Citric acid is preparing application in SC 69124 sodium freeze-dried preparation composition and combinations thereof and preparation method | |
CN102357081A (en) | Composite fat-soluble vitamin freeze-dried powder injection and preparation method thereof | |
CN102895178B (en) | Strong solution-type moxifloxacin hydrochloride injection and preparation method thereof | |
CN104800172A (en) | Carbazochrome sodium sulfonate powder injection for injection and preparation method thereof | |
CN101904862A (en) | Water-soluble vitamin composition freeze-drying preparation for injection | |
CN101204371A (en) | Vitamin C injection and preparation method thereof | |
CN114904001A (en) | Pharmaceutical composition containing vonoprazan acetate and preparation method thereof | |
CN102526089B (en) | Pharmaceutical composition containing 13 vitamins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI HUAHUI KAIDE PHARMACEUTICAL CO.,LTD. Free format text: FORMER OWNER: PENG JIANHUA Effective date: 20090410 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090410 Address after: A District, Shanxi Pharmaceutical Industrial Park, Jinzhong economic and Technological Development Zone, Shanxi Province, China: 030600 Patentee after: SHANXI HUAHUI KAIDE PHARMACEUTICAL Co.,Ltd. Address before: Beijing City, Xuanwu District Guanganmen Avenue 319 GITIC garden C block 19 layer zip code: 100053 Co-patentee before: Cheng Hui Patentee before: Peng Jianhua |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160229 Address after: 030600 A zone, Shanxi pharmaceutical industry park, Jinzhong economic and Technological Development Zone, Shanxi Patentee after: SHANXI DEYUANTANG PHARMACEUTICAL CO.,LTD. Address before: 030600 A zone, Shanxi pharmaceutical industry park, Jinzhong economic and Technological Development Zone, Shanxi Patentee before: SHANXI HUAHUI KAIDE PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080102 |
|
CF01 | Termination of patent right due to non-payment of annual fee |